RNXT

RenovoRx, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.16

Price (1 Year)

$2.39 $0.79

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %29.3 / %30
Non-compliant revenue / Total income %7.6 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Website

Analysis (Turkish): RNXT Hissesi Caiz mi, Helal mi? RenovoRx, Inc. Katılım Analizi